Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report

Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report

Abstract Background It is well known that vascular endothelial growth factor (VEGF) inhibitors can cause proteinuria. The incidence of proteinuria is high for bevacizumab, a humanized monoclonal antibody directed against VEGF, but the range of proteinuria rarely becomes nephrotic (2.2% occurrence ac...

Full description

Bibliographic Details
Main Authors: Ryo Yamada, Takao Okawa, Ken Matsuo, Makoto Suzuki, Noriko Mori, Kiyoshi Mori
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Nephrology
Subjects:
Bevacizumab
Nephrotic syndrome
Proteinuria
Ramucirumab
Thrombotic microangiopathy
Online Access:http://link.springer.com/article/10.1186/s12882-018-1194-9

Internet

http://link.springer.com/article/10.1186/s12882-018-1194-9

Similar Items